Cue Health to Develop Omicron-Genotyping COVID-19 Test in Partnership with the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA)

SAN DIEGO, Jan. 6, 2022 /PRNewswire/ — Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it will develop an Omicron-Genotyping COVID-19 test to be used in professional point-of-care settings as part of the company’s ongoing work with the U.S. Department…